Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
15 Placebos Trials Near You
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerQuillivant XR for ADHD in Down Syndrome
Cincinnati, Ohio
Children with Down syndrome (DS) have a 3-5 time greater prevalence of Attention Deficit Hyperactivity Disorder (ADHD) than typically developing (TD) children. Despite this higher risk of ADHD, rates of stimulant medication treatment are disproportionately low in children with DS+ADHD, even though stimulants are the most efficacious ADHD treatment and are recommended by consensus guidelines for use in children with intellectual disability and ADHD.
The investigators propose the first randomized clinical trial (RCT) of stimulant medication in children with DS+ADHD. This RCT may provide evidence regarding the short- and long-term safety and efficacy of stimulant use in children with DS+ADHD, both with and without CHD. All children enrolled in the study will complete a comprehensive assessment battery evaluating ADHD diagnostic criteria, as well as behavioral, cognitive, academic, and functional impairments.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:6 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Psychoses, Bipolar, Organic Brain Injury, Heart Conditions, Severe OSA, Pregnancy, Others
Must Not Be Taking:ADHD Stimulants, MAOIs
100 Participants Needed
Troriluzole for Spinocerebellar Ataxia
Ann Arbor, Michigan
This trial is testing whether a medication called Troriluzole can help people with spinocerebellar ataxia by balancing a brain chemical to prevent damage. Troriluzole is related to riluzole, which has been shown to prolong survival and slow functional deterioration in patients with ALS.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Spasticity, Dystonia, Liver Disease, Others
299 Participants Needed
Heparin for Heart Disease
London, Ontario
Patients undergoing cardiac catheterization will be randomized to 3 groups: no anticoagulant, low dose anticoagulant and high dose anticoagulant.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Abnormal Circulation, Prior Thrombosis, Others
Must Not Be Taking:Anticoagulants
3600 Participants Needed
Duloxetine for Postoperative Pain After Knee Surgery
Chicago, Illinois
This trial is testing if duloxetine can help reduce pain and opioid use in patients after knee replacement surgery. It focuses on patients who often have severe pain or heightened pain sensitivity. Duloxetine may work by altering brain chemicals to lessen pain signals. Duloxetine has been shown to have significant pain-relieving effects for managing chronic pain associated with conditions like fibromyalgia and diabetic peripheral neuropathic pain.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Psychiatric Disorders, Heavy Alcohol, Others
Must Not Be Taking:SSRIs, SNRIs, Serotonergic Drugs
504 Participants Needed
Poop Transplant for Pouchitis
Hamilton, Ontario
This is a randomized double-blind placebo controlled trial involving a single centre (McMaster University) recruiting patients from Hamilton, ON and the surrounding regions, to evaluate whether fecal microbiota transplantation once weekly for six weeks increases the remission rate compared to placebo in patients with active pouchitis.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 99
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Illness, C. Difficile, Others
34 Participants Needed
This trial tests if extending vancomycin treatment with a gradually reduced dose can prevent recurrence of Clostridium difficile infection in adults. The idea is that a longer, gradually reduced antibiotic course will better eliminate the bacteria and lower the risk of the infection coming back. Vancomycin taper regimens are commonly used for the treatment of recurrent Clostridium difficile infections.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 100
Sex:All
Key Eligibility Criteria
Disqualifiers:Not Listed
263 Participants Needed
Cannabis Effects on Driving Performance
Toronto, Ontario
Epidemiological studies suggest that the use of cannabis is associated with an increase in the risk of motor vehicle collisions. It is also known that younger users may be at increased risk for motor vehicle collisions. Further, the frequency with which cannabis is used may be an important variable in determining the effects of cannabis on driving. The purpose of the present study will be to investigate the effects of cannabis on simulated driving in young as compared to middle-aged drivers. Half of the participants will be occasional users of cannabis and half will be frequent users of cannabis.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:19 - 45
Sex:All
Key Eligibility Criteria
Disqualifiers:Therapeutic Cannabis, Psychiatric Conditions, Substance Use Disorder, Others
Must Not Be Taking:Sedatives, Psychoactive Drugs, Antihypertensives
128 Participants Needed
Sleep Medications for Healthy Volunteers
Silver Spring, Maryland
The primary objective of this study is to evaluate two pharmacotherapeutic approaches to sleep induction, both of which have been shown to be effective hypnotics, but may have unique side effect profiles. These profiles may have markedly different impacts on performance in a military setting. In this randomized, double-blind, placebo controlled study, the side effects of these drugs will be compared - suvorexant, a dual orexin receptor antagonist and zolpidem, a non-benzodiazepine gamma-aminobutyric acid (GABA) A agonist - in healthy controls comparable in age and gender to the target military population.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1
Age:18 - 39
Sex:All
Key Eligibility Criteria
Disqualifiers:Sleep Disorders, Neurologic Disorders, Cardiovascular Disease, Psychiatric Disorder, Others
Must Not Be Taking:Sleep Aids, Benzodiazepines, Amphetamines, Others
90 Participants Needed
Dysport® + Bracing for Adolescent Idiopathic Scoliosis
Baltimore, Maryland
This study evaluates the combined effect of botulinum toxin A (administered as Dysport® (Ipsen Pharmaceuticals)) and bracing in children with adolescent idiopathic scoliosis. Two thirds of patients will be treated with Dysport® and bracing, while the remaining patients will be treated with placebo and bracing.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:10 - 16
Sex:All
Key Eligibility Criteria
Disqualifiers:Congenital Scoliosis, Neuromuscular Scoliosis, Surgery, Others
Must Not Be Taking:Neuromuscular Drugs
90 Participants Needed
Suvorexant for Opioid Use Disorder
Baltimore, Maryland
This study is designed to elucidate the role of the orexin neurotransmitter system in sleep disturbance and circadian rhythms of stress that might in turn influence relapse behaviors in persons on medication-assisted treatments (MAT) who are in early recovery from opioid use disorder (OUD). Briefly, the study will enroll recently abstinent OUD patients (N=200) maintained on either extended-release naltrexone (XR-NTX), buprenorphine, or methadone. Within each MAT group, participants will be randomized to either suvorexant or placebo. The study is expected to have a 20% treatment attrition rate which will result in N=160 completers in the entire study. Patients will be recruited from and treated at Ashley Addiction Treatment, Addiction Treatment Services at Johns Hopkins Bayview Medical Center, Man Alive, or community providers.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:21 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Serious Mental Illness, Stimulant Use, Pregnancy, Others
Must Be Taking:Methadone, Buprenorphine, XR-NTX
200 Participants Needed
GLP-1 for Type 1 Diabetes
Baltimore, Maryland
The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in T1DM.
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 50
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Hypertension, Heart Disease, Others
Must Not Be Taking:Anticoagulants, Antidepressants, Antipsychotics, Others
40 Participants Needed
Fatty Acid Elevation for Obesity
Chapel Hill, North Carolina
This trial involves giving healthy individuals either a fat solution or a saltwater solution to see how it affects their brain's ability to transport glucose. The study focuses on non-diabetic, normal weight people to understand how sudden increases in blood fatty acids impact brain energy use. Researchers hope to learn more about brain glucose transport in relation to obesity.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 45
Sex:All
Key Eligibility Criteria
Disqualifiers:Hepatic, Renal, Neurologic, Psychiatric, Others
Must Not Be Taking:Steroids, Metabolism-altering Drugs
40 Participants Needed
Medication + Nerve Stimulation for HIV
New York, New York
The study team's prior research has shown that dysfunction of a specific nerve, called the vagus nerve, is associated with small intestinal bacterial overgrowth (SIBO), and that SIBO is associated with signs of inflammation in the blood of people living with HIV (PLWH). This research will explore pathways linking vagal dysfunction to inflammation in HIV, focusing on the gastrointestinal tract, and study whether a medication called pyridostigmine and stimulation of the vagus nerve are beneficial therapies.
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Dysphagia, GI Obstruction, Crohn's, Others
Must Not Be Taking:Sympathomimetics, Prokinetics, Antibiotics, Others
55 Participants Needed
eRapa for Bladder Cancer Prevention
Dallas, Texas
This study is evaluating whether a drug which is used to prevent organ rejection in transplant patients may also help prevent cancer from returning.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Muscle-invasive Cancer, Active Cancer, Others
Must Not Be Taking:Oral Glucocorticoids, Rapamycin
166 Participants Needed
Brain Imaging Study for Fibromyalgia
Halifax, Nova Scotia
Drugs used for managing Fibromyalgia pain have not proven to be effective and pain continues to cost Canadians $60 billion a year without truly helping those who suffer. The study proposes to investigate the factors related to a person that can enhance or reduce the effectiveness of pain treatments in people suffering with Fibromyalgia pain. Treatment response to painkillers in a person may be related to their brain, social, and psychological makeup. The investigators aim to study these factors to identify and develop feasible and robust indicators based on a person's biological makeup (also called biomarkers). These biomarkers will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people. These measures will offer new opportunities for improving treatment such as by tailoring treatment to meet the specific needs of each patient based on his/her biological and psychological makeup. Towards the specific aim, data will first be collected in several experimental domains for studying treatment expectations (cognitive, psychosocial, brain-related). These 'experimental' data will be compared between Fibromyalgia (FM) and healthy participants to yield new understanding of the factors that govern treatment response. At the end of experimental data collection, the investigators will collect data in the 'clinical' domain. Hence, at the end of the experimental sessions, a subset of FM participants will receive a mock drug (placebo disguised as an approved pain treatment) and another subset will provide pain ratings only and hence serve as a waiting list control for the placebo trial. Data will be studied in steps to understand factors that mediate treatment outcomes and finally the investigators will use advanced computational tools used for big data analysis and aim to identify factors that can be used as biomarkers and precision medicine tools.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiac, Respiratory, Nervous System, Others
35 Participants Needed
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.How do clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length is 12 months.How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.Do I need to be insured to participate in a medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.What are the newest clinical trials ?
Most recently, we added Cannabis Effects on Driving Performance, Duloxetine for Postoperative Pain After Knee Surgery and Brain Imaging Study for Fibromyalgia to the Power online platform.Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.